Company Profile

The Valens Company Inc. is a Canada-based company, which is engaged in the manufacturing of cannabinoid-based products. It operates through two segments: Canada and United States and International. Canada segment includes all business-to-business and business-to-consumer activity within Canada. This includes toll processing and co-packing, product sales, and analytical testing. United States and International segment include all activity related to the Green Roads CBD health and wellness manufacturing facility in Florida, United States. Its products are formulated for the recreational, health and wellness, and medical consumer segments and are offered across all cannabis product categories. It also manufactures, distributes, and sells a range of cannabidiol (CBD) products in the United States through its subsidiary Green Roads, Inc. (Green Roads), and distributes medicinal cannabis products to international markets through its subsidiary Valens Australia Pty Ltd (Valens Australia).

Employees

445

Sector

Pharmaceuticals

More about the company

11-03	The Valens Company Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-07-30	The Valens Company Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-04-30	The Valens Company Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
23-01-17	The Valens Company Inc.(NasdaqCM:VLNS) dropped from NASDAQ Composite Index	CI
23-01-16	SNDL Inc. completed the acquisition of remaining 91.9% stake in The Valens Company Inc..	CI
23-01-03	Valens Gets Final Court Order Approving Proposed Arrangement With SNDL	MT
23-01-03	The Valens Co Obtains Final Court Order Approving Proposed Arrangement With SNDL	MT
23-01-03	The Valens Company Obtains Final Court Order Approving Proposed Plan of Arrangement With SNDL	MT
22-12-14	The Valens Company Granted Additional 180-Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	MT
22-12-14	The Valens Co Brief: Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	MT
22-12-14	Valens Gets Additional 180-Day Period to Regain Nasdaq Compliance	MT
22-11-29	The Valens Company Brief: Says Shareholders Vote in Favour of the Arrangement with SNDL	MT
22-11-22	The Valens Company Brief: Both Institutional Shareholder Services and Glass Lewis & Co. Recommend Shareholders of Co Vote For Proposed Arrangement With SNDL Inc.	MT

22-10-14	The Valens Company Buy Rating Reiterated at Stifel GMP Following FQ3 Results; Price Target Kept at C$1.20	MT
22-08-23	The Valens Company Keep Buy Rating From BMO Capital Ahead of Acquistion by SNDL; Price Target Cut to C$1.20	MT
22-07-15	The Valens Company Reiterated at Buy at Stifel GMP Following Fiscal Second-Quarter Results	MT
22-07-14	The Valens Company Buy Rating Maintained at Stifel GMP Following Fiscal Second-Quarter Results	MT
21-10-15	VALENS : Shares Decline More than 4%, Desjardins Says EBITDA Positive Timeline Now Q2 Fiscal 2022	MT

23-01-17	SNDL Completes Acquisition of The Valens Company	AQ
23-01-03	THE VALENS COMPANY OBTAINS FINAL COURT ORDER APPROVING THE PROPOSED PLAN OF ARRANGEMENT WITH SNDL	AQ
22-12-13	The Valens Company Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	AQ
22-11-29	Valens Shareholders Vote in Favour of the Arrangement with SNDL	PR
22-11-22	BOTH LEADING INDEPENDENT PROXY ADVISORS RECOMMEND SHAREHOLDERS OF THE VALENS COMPANY INC. VOTE FOR THE PROPOSED ARRANGEMENT WITH SNDL INC.	AQ

21-12-09	Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 9 décembre 2021
21-12-09	Valens : Le producteur de cannabis The Valens va faire ses premiers pas sur le Nasdaq
21-09-30	Eiffage : construit un institut psychiatrique en Belgique
21-05-19	Eiffage : chargé de la transformation d'une gare en Belgique
21-03-29	Eiffage : mobilisé pour les travaux de The First, à Bruxelles

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-11-30	Adam Shea	Option	Executive/Senior Manager	3,138	0.0039%
22-11-30	Adam Shea	Option	Executive/Senior Manager	2,785	0.0034%
22-11-30	Adam Shea	Option	Executive/Senior Manager	2,785	0.0034%

The Valens Company Inc. Stock

Stocks

VLNS

CA91914P6030

Pharmaceuticals

Latest news : The Valens Company Inc.

Analysts' recommendations: The Valens Company Inc.

Press Releases: The Valens Company Inc.

News in other languages: The Valens Company Inc.

Quotes and Performance

Latest insider transactions

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THE VALENS COMPANY INC.	-0.98%	-1.94%	-	-	59.39M
ELI LILLY AND COMPANY	+2.96%	+3.01%	+59.87%	+173.31%	1,070B
JOHNSON & JOHNSON	+3.05%	+5.23%	+72.11%	+67.81%	624B
ABBVIE INC.	-0.04%	+1.20%	+35.72%	+87.93%	450B
ROCHE HOLDING AG	-2.58%	-2.07%	+27.62%	+22.57%	328B
NOVARTIS AG	+1.36%	+0.17%	+29.90%	+49.33%	284B
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	217B
AMGEN INC.	+0.45%	+1.65%	+25.65%	+68.35%	198B
GILEAD SCIENCES, INC.	+5.21%	+7.93%	+21.99%	+83.23%	161B
PFIZER INC.	+1.48%	-0.04%	-4.64%	-32.25%	135B
Average	+0.67%	+1.65%	+26.94%	+53.47%	385.27B
Weighted average by Cap.	+1.50%	+1.63%	+41.85%	+87.34%